Fabry disease is sometimes known as Anderson-Fabry disease or alpha-galactosidase-deficient disease. Galactosidase A deficiency is an X-linked, hereditary lysosomal storage disease caused by a lack of the enzyme galactosidase A. (an enzyme required to metabolize lipids, fat-like substances that include oils, waxes, and fatty acids). The defective gene causes lipid formation in different parts of the body, including the autonomic nervous system, cardiovascular system, eyes, and kidneys, to reach dangerous amounts. Chronic pain, acroparesthesia, gastrointestinal difficulties, distinctive skin lesions (angiokeratomata), increasing renal impairment, cardiomyopathy, and stroke are all common signs of this multisystem condition.
Market Drivers for Fabry Disease Treatment
Several regulatory organizations in major locations have recently approved innovative drugs to treat Fabry disease. Over the projected period, the approval and introduction of such novel drugs in the area is expected to considerably support worldwide Fabry Disease Treatment Market growth.
For example, Amicus Therapeutics, Inc.'s medicine Galafold was approved by the US Food and Drug Administration (FDA) in August 2018. (migalastat). It is the first oral medicine approved for the treatment of Fabry disease in adults.
Regional Analysis of the Fabry Disease Treatment Market
Due to the penetration of key companies in key regions of Europe with their novel Fabry disease medicines, the Europe Fabry disease treatment market is likely to rise dramatically over the forecast period. In March 2017, Amicus Therapeutics Inc. launched Galafold (Migalastat) in Italy and Spain for the treatment of Fabry disease (in January 2018)
Regional Analysis of the Fabry Disease Treatment Market
Due to the penetration of key companies in key regions of Europe with their novel Fabry disease medicines, the Europe Fabry disease treatment market is likely to rise dramatically over the forecast period. In March 2017, Amicus Therapeutics Inc. launched Galafold (Migalastat) in Italy and Spain for the treatment of Fabry disease (in January 2018)
Market Restraint for Fabry Disease Treatment
According to the National Fabry Disease Foundation, Fabry condition is an extremely rare disease that affects about 1 in 50,000 people. The diagnosis of Fabry disease is verified by proving an enzyme deficiency in males and finding the specific GLA gene mutation in both males and females.
Key Players in the Fabry Disease Treatment Market
Amicus Therapeutics Inc., Sanofi Genzyme (a Sanofi S.A. company), Idorsia Pharmaceuticals Ltd., Protalix BioTherapeutics, Inc., AvroBio Inc., JCR Pharmaceuticals Co., Ltd., Resverlogix Corp., and Ozmosis Research Inc. are some of the major companies in the global Fabry disease treatment market.
0 Comments